Is Neumora Therapeutics, Inc. (NMRA) overvalued? · $283.5M cap
Neumora Therapeutics, Inc. (NMRA) is a biotechnology company listed on NASDAQ.
This page asks whether Neumora Therapeutics, Inc. (NMRA) looks expensive on cached numbers — not a short thesis.
No cached income statement for NMRA, so there is no earnings base to call rich or cheap.
NMRA currently screens at market cap $283.5M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next NMRA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the NMRA stock page for the full model, not this heading.
Not investment advice.